Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2340620 | 1.00 | REN (0.53) | RENHTTMEN1KMT2ALMNA | |
| SCHEMBL2345474 | 0.89 | REN (0.44) | RENHTTMEN1KMT2ALMNA | |
| SCHEMBL2345055 | 0.87 | REN (0.56) | RENHTTMEN1KMT2ALMNA | |
| SCHEMBL8292274 | 0.86 | KDM4E (0.41) | RENHTTMEN1KMT2ALMNA | |
| SCHEMBL2340514 | 0.86 | LMNA (0.47) | RENHTTMEN1KMT2ALMNA | |
| SCHEMBL2340878 | 0.86 | KDR (0.55) | RENHTTMEN1KMT2AKDM4E | |
| SCHEMBL2349349 | 0.86 | REN (0.42) | RENHTTMEN1KMT2ALMNA | |
| SCHEMBL8292277 | 0.85 | KDR (0.54) | RENHTTMEN1KMT2AKDM4E | |
| SCHEMBL8290595 | 0.82 | REN (0.41) | RENHTTMEN1KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL4941404 | 0.82 | CHRNA7 (0.49) | RENHTTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007504238-A | — | — | 2007-03-01 | — | — | JP | claimed |
| CN-1870991-A | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) | AVENTIS PHARMA INC (US) | 2006-11-29 | — | — | CN | claimed |
| EP-1663202-A1 | SUBSTITUTED INDOLES AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) | Aventis Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005023246-A1 | SUBSTITUTED INDOLES AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-17 | — | — | WO | claimed |
| US-20050054631-A1 | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-10 | — | — | US | claimed |
| US-8008491-B2 | poly(adenosine 5'-diphosphate ribose) polymerase inhibitors such as 1-phenyl-2-(piperazin-1-yl)-1,3-dihydropyrrolo[2,3-b]pyridine-3-carboxaldehyde, used in the treatment and/or prevention central nervous system and cardiovascular disorders | AVENTIS PHARMACEUTICALS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008491-B2 | poly(adenosine 5'-diphosphate ribose) polymerase inhibitors such as 1-phenyl-2-(piperazin-1-yl)-1,3-dihydropyrrolo[2,3-b]pyridine-3-carboxaldehyde, used in the treatment and/or prevention central nervous system and cardiovascular disorders | AVENTIS PHARMACEUTICALS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20080255350-A1 | SUBSTITUTED AZA-INDOLES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255350-A1 | SUBSTITUTED AZA-INDOLES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7405300-B2 | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) | AVENTIS PHARMAVEUTICALS INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405300-B2 | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) | AVENTIS PHARMAVEUTICALS INC. (US) | 2008-07-29 | — | — | US | disclosed |
| CN-1870991-A | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) | AVENTIS PHARMA INC (US) | 2006-11-29 | — | — | CN | disclosed |
| EP-1663202-A1 | SUBSTITUTED INDOLES AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) | Aventis Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023246-A1 | SUBSTITUTED INDOLES AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023246-A1 | SUBSTITUTED INDOLES AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054631-A1 | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054631-A1 | Substituted indoles as inhibitors of poly (ADP-ribose) polymerase (PARP) | PARP1, PARP11, PARP3 | REN 1290/4885HTT 417/4885MEN1 2781/4885 |
| US-20080255350-A1 | SUBSTITUTED AZA-INDOLES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | PARP1, PARP11, PARP15 | REN 1677/4885HTT 626/4885MEN1 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.